Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

172682 items
11:27 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Sarepta's DMD candidate leads to microdystrophin expression of 76.2% in Phase I/IIa

Sarepta Therapeutics Inc. (NASDAQ:SRPT) reported on June 19 preliminary data from a Phase I/IIa trial evaluating AAVrh74.MHCK7.micro-Dystrophin to treat Duchenne muscular dystrophy (DMD). In three DMD patients in the open-label, U.S. trial, the microdystrophin gene therapy...
11:26 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Teva discontinues Phase III chronic cluster headache trial of fremanezumab

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) discontinued a Phase III trial of fremanezumab (TEV-48125) to prevent chronic cluster headache based on a prespecified futility analysis. The company said a Phase III trial of the...
11:26 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy....
11:26 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

AZ reports Phase III data for hairy cell leukemia candidate

AstraZeneca plc (LSE:AZN; NYSE:AZN) reported data from the Phase III 1053 trial in 80 patients with relapsed or refractory hairy cell leukemia who have received at least two prior therapies showing that moxetumomab pasudotox (formerly...
11:25 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) reported that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with osteoarthritis (OA) of the knee. Cingal comprises a single injection of sodium hyaluronate...
11:25 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Antibodies neutralize Catalyst's Factor IX variant

Catalyst Biosciences Inc. (NASDAQ:CBIO) reported that two patients developed neutralizing antibodies to its CB 2679d (ISU 304). The antibodies were observed after treatment in the sixth and latest dose cohort of a Phase I/II trial...
11:09 AM, Jun 22, 2018  |  BC Week In Review | Company News  |  Other News

UC Regents get CRISPR guide RNA patent in U.S.

The U.S. Patent Office on June 19 granted a patent related to CRISPR-Cas9 gene editing technology to the Regents of the University of California, the University of Vienna and Emmanuelle Charpentier covering use of guide...
11:09 AM, Jun 22, 2018  |  BC Week In Review | Company News  |  Other News

NIH ends funding for alcohol study

NIH said it will stop funding the Moderate Alcohol and Cardiovascular Health (MACH) study after concluding that NIH employees violated agency policies to secure its funding and potentially biased its design towards the alcohol industry. Led...
11:09 AM, Jun 22, 2018  |  BC Week In Review | Company News  |  Deals

Roche snaps up rest of Foundation to enhance global access

Roche (SIX:ROG; OTCQX:RHHBY) is acquiring the remaining shares of cancer diagnostics company Foundation Medicine Inc. (NASDAQ:FMI) that it does not already own for $137 per share in cash, or $2.4 billion. In 2015, Roche had acquired...
11:08 AM, Jun 22, 2018  |  BC Week In Review | Company News  |  Other News

Gawande to head Amazon-Berkshire-Chase healthcare company

Amazon.com Inc. (NASDAQ:AMZN), Berkshire Hathaway Inc. (NYSE:BRK.A; NYSE:BRK.B) and JPMorgan Chase & Co. (NYSE:JPM) hired Atul Gawande as CEO of their new company focused on U.S. employee healthcare, effective July 9. His experience draws from...

Pages